睿知中国疾病研究地图
候选清单0

福州福建医科大学

福建医科大学附属协和医院

Fujian Medical University Union Hospital

在本站收录的 53 种疾病中,这家医院列在其中 23 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

福建医科大学附属协和医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma3 篇牵头论文
  2. 食管鳞状细胞癌Oesophageal squamous cell carcinoma49 篇牵头论文牵头 4 项开放试验
  3. 肝细胞癌Hepatocellular carcinoma47 篇牵头论文
  4. 胃癌Stomach cancer166 篇牵头论文牵头 12 项开放试验
  5. 骨肉瘤Osteosarcoma0 篇牵头论文
  6. 胃肠道间质瘤Gastrointestinal stromal tumour13 篇牵头论文牵头 2 项开放试验
  7. 神经母细胞瘤Neuroblastoma1 篇牵头论文
  8. 多发性骨髓瘤Multiple myeloma6 篇牵头论文
  9. B 细胞急性淋巴细胞白血病B-cell acute lymphoblastic leukaemia4 篇牵头论文
  10. 再生障碍性贫血Aplastic anaemia2 篇牵头论文
  11. 血友病 AHaemophilia A6 篇牵头论文
  12. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
  13. 范可尼贫血Fanconi anaemia1 篇牵头论文
  14. 重症肌无力Myasthenia gravis0 篇牵头论文
  15. 烟雾病Moyamoya disease4 篇牵头论文
  16. 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis0 篇牵头论文
  17. 特发性肺纤维化Idiopathic pulmonary fibrosis4 篇牵头论文
  18. 肺淋巴管平滑肌瘤病Lymphangioleiomyomatosis1 篇牵头论文
  19. 肌萎缩侧索硬化症Amyotrophic lateral sclerosis11 篇牵头论文
  20. 脊髓性肌萎缩症Spinal muscular atrophy0 篇牵头论文
  21. 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
  22. IgA 肾病IgA nephropathy0 篇牵头论文
  23. 先天性巨结肠Hirschsprung disease1 篇牵头论文

未列出的收录疾病:肝母细胞瘤、视网膜母细胞瘤、脊索瘤、尤文肉瘤、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、视神经脊髓炎谱系疾病、IgG4相关性疾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。

牵头论文
3
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

福州有 5 家医院列在鼻咽癌下全国有 176 家医院列在鼻咽癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    早期复发性鼻咽癌:辅助治疗与单纯手术比较Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    分期
    III期
    开始
    2024-06
    登记号
    NCT06228079

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院;另有 6 家列出的医院为研究中心上海、南宁、深圳、福州

  2. 正在招募
    局部晚期复发性鼻咽癌:新辅助治疗与辅助治疗比较Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    分期
    III期
    开始
    2024-07
    登记号
    NCT06235203

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院;另有 6 家列出的医院为研究中心上海、南宁、深圳、福州

  3. 即将招募
    早期复发性鼻咽癌:手术与调强放疗(IMRT)的效果比较Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    分期
    III期
    开始
    2021-03
    登记号
    NCT04215510

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院;另有 3 家列出的医院为研究中心上海、南昌、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题免疫治疗复发与转移
论文中的科室耳鼻喉/头颈外科放疗科
牵头的论文3
  1. CDCP1 promotes the malignant phenotypes of nasopharyngeal carcinoma via the Wnt/β-catenin signaling pathway.2025BMC biotechnology免费全文
  2. Research on the changes in the disease burden of nasopharyngeal carcinoma caused by global occupational formaldehyde exposure from 1990 to 2021 and prediction of future trends.2025Frontiers in public health免费全文
  3. The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma.2021Applied immunohistochemistry & molecular morphology : AIMM
它在 ClinicalTrials.gov 上的全部试验(任何状态)12
  1. Adjuvant vs Surgery Only in Early-stage Recurrent NPC正在招募NCT06228079研究中心III期2024-06 启动
  2. Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC正在招募NCT06235203研究中心III期2024-07 启动
  3. Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT即将招募NCT04215510研究中心III期2021-03 启动
  4. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC状态不明NCT05350891研究中心II期2022-05 启动
  5. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  6. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images状态不明NCT05627310研究中心2022-11 启动
  7. Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma已完成NCT04823468研究中心不分期2021-07 启动
  8. Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma状态不明NCT05011227研究中心II期2021-08 启动
  9. A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients状态不明NCT04061278研究中心III期2019-08 启动
  10. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer已完成NCT03581786研究中心III期2018-10 启动
  11. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  12. Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer状态不明NCT01074021研究中心III期2009-10 启动
PubMed 以外找到的论文(未计入)7
  1. LBA103 Early versus routine oral nutritional supplements during concurrent chemoradiotherapy for nasopharyngeal carcinoma: Efficacy and cost-utility analysis in a multicenter randomized controlled trial2025Annals of Oncology会议摘要
  2. Post‑irradiation mastoid mucosa disease in patients with nasopharyngeal carcinoma after radiotherapy: A large‑cohort and long‑term study2025Oncology Letters论文
  3. Validation and Development of a Refined M1 Category for Nasopharyngeal Carcinoma Based on the Ninth-Version of AJCC/UICC TNM Staging System in the Immunotherapy Era: A Multicenter Cohort Study2025International Journal of Radiation Oncology*Biology*Physics论文
  4. Detection of cytotoxic effects of carboplatin in human nasopharyngeal carcinoma epithelioid cell line CNE-1 by Raman spectroscopy combined with multivariate statistical analysis2024Spectroscopy Letters论文
  5. Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.2024Journal of Clinical Oncology会议摘要
  6. Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.2022Journal of Clinical Oncology会议摘要
  7. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncology论文

打开 PubMed 检索ClinicalTrials.gov

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 49 篇,占 1.7%。

牵头论文
49
2021–2025 年
牵头试验
9
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 131320222023: 5520232024: 8820242025: 18182025

福州有 5 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
    分期
    II期
    开始
    2024-04
    登记号
    NCT06510660

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  2. 正在招募
    Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
    分期
    II期
    开始
    2024-07
    登记号
    NCT06601309

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  3. 正在招募
    Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
    分期
    不分期
    开始
    2023-05
    登记号
    NCT03734952

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  4. 即将招募
    A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
    分期
    III期
    开始
    2026-10
    登记号
    NCT07788001

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术新辅助与综合治疗分子标志物与基因
论文中的科室放疗科普外/肝胆胰外科病理/检验科
牵头的论文49
  1. SRRN: A regional lymph node ratio-based staging system enhancing prognostic accuracy in esophageal squamous cell carcinoma.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  2. Combined immunoscore and pan-immune inflammation value associated with pathological response and survival outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunotherapy.2026International journal of surgery (London, England)免费全文
  3. Spatial metrics of lymph node metastasis refine prognostic stratification of T1-T2 esophageal squamous cell carcinoma.2026The Journal of thoracic and cardiovascular surgery
  4. Severe postoperative complications after minimally invasive esophagectomy reduce the long-term prognosis of well-immunonutrition patients with locally advanced esophageal squamous cell carcinoma.2025Annals of medicine免费全文
  5. Preoperative immune prognostic index predicts the prognosis and postoperative adjuvant chemotherapy benefits of esophageal squamous cell carcinoma after minimally invasive esophagectomy.2025BMC gastroenterology免费全文
  6. Tumor Regression Grade as a Predictor of Adjuvant Therapy Benefits in Esophageal Squamous Cell Carcinoma Patients After Neoadjuvant Therapy.2025Cancer medicine免费全文
  7. Prediction of T2/T3 Staging in Patients with Volume-Equivalent Esophageal Squamous Cell Carcinoma on the Basis of PET/CT Radiomics.2025Computer methods and programs in biomedicine
  8. A novel nomogram for predicting long-term survival in patients with esophageal squamous cell carcinoma after minimally invasive esophagectomy.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  9. Comparison of long-term outcomes of 2.5- and 3-field lymph node dissections for esophageal squamous cell carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. The role of pathological response in predicting the benefit of adjuvant therapy after neoadjuvant chemoimmunotherapy in patients with esophageal cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  11. Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  12. Hsa_circRNA_0101125 Promotes Proliferation, Migration, and Invasion of Esophageal Squamous Cell Carcinoma via miR-143-3p/ZNF148 Axis.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology免费全文
  13. The neoadjuvant esophageal score: a prognostic tool for predicting survival and postoperative complications in esophageal squamous cell carcinoma.2025Frontiers in immunology免费全文
  14. Establishment and validation of survival nomogram score staging for esophageal squamous cell carcinoma patients after minimally invasive surgery combined with immune prognostic index and clinicopathological features.2025Frontiers in immunology免费全文
  15. Application of machine learning based on habitat imaging and vision transformer to predict treatment response of locally advanced esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy: a multi-center study.2025Frontiers in immunology免费全文
  16. The prognostic power of major pathological response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multi-center cohort study.2025Frontiers in immunology免费全文
  17. Identification of disulfidptosis in esophageal squamous cell carcinoma based on single-cell and bulk RNA-seq data to predict prognosis and treatment response.2025Frontiers in immunology免费全文
  18. Preoperative albumin-to-fibrinogen ratio as a predictor of postoperative hospital stay in locally advanced esophageal squamous cell carcinoma after neoadjuvant therapy.2025Scientific reports免费全文
  19. Impact of clinical decisions on patient outcomes after neoadjuvant therapy in locally advanced resectable esophageal squamous cell carcinoma.2025Surgical endoscopy
  20. The enhanced pathological response from additional immunotherapy improved recurrence-free survival for esophageal squamous cell carcinoma: a multi-center cohort study.2025Surgical endoscopy
  21. Impact of Interval to Esophagectomy After Neoadjuvant Immunochemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Retrospective Cohort Analysis.2025Thoracic cancer免费全文
  22. Camrelizumab in combination with chemotherapy versus concurrent chemoradiotherapy for the conversion of locally advanced unresectable oesophageal squamous carcinoma: protocol for a two-arm, open-label phase II trial.2024BMJ open免费全文
  23. BCLAF1 drives esophageal squamous cell carcinoma progression through regulation of YTHDF2-dependent SIX1 mRNA degradation.2024Cancer letters
  24. LncRNA LUESCC promotes esophageal squamous cell carcinoma by targeting the miR-6785-5p/NRSN2 axis.2024Cellular and molecular life sciences : CMLS免费全文
  25. Prognostic value of immunosuppression scores in patients with esophageal squamous cell carcinoma: a multicenter study.2024Frontiers in immunology免费全文
  26. Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study.2024Frontiers in immunology免费全文
  27. SORBS2-Mediated inhibition of malignant behaviors in esophageal squamous cell carcinoma through TIMP3.2024International immunopharmacology
  28. Elucidating the role of CYFIP2 in conferring cisplatin resistance in esophageal squamous cell carcinoma.2024Scientific reports免费全文
  29. Comparison of indocyanine green-near-infrared fluorescence guided and traditional mediastinal lymphadenectomy during radical esophagectomy: A randomized controlled trial.2024SurgeryRCT
  30. Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy.2023International journal of clinical oncology
  31. Impact of minimally invasive total mesoesophageal excision and minimally invasive esophagectomy on failure patterns of locally advanced esophageal squamous cell carcinoma: a matched cohort study with long-term follow-up.2023Surgical endoscopy
  32. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.2023Trials免费全文
  33. Inflammatory and Nutritional Status Influences Outcomes of Minimally Invasive Esophagectomy.2023World journal of surgery
  34. Prediction of pulmonary metastasis in esophageal carcinoma patients with indeterminate pulmonary nodules.2023World journal of surgical oncology免费全文
  35. Recurrence index predicts the prognosis of patients with pathological T1 esophageal squamous cell carcinoma.2022Asian journal of surgery
  36. Prognostic variables for conditional survival in patients with esophageal squamous cell carcinoma who underwent minimally invasive surgery.2022BMC cancer免费全文
  37. Pirfenidone for the prevention of radiation-induced lung injury in patients with locally advanced oesophageal squamous cell carcinoma: a protocol for a randomised controlled trial.2022BMJ open免费全文
  38. PolyC-RNA-binding protein 1 (PCBP1) enhances tropomyosin 3 (TPM3) mRNA stability to promote the progression of esophageal squamous cell carcinoma.2022Bioengineered免费全文
  39. Residual tumor model in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy: Frequently involves the mucosa and/or submucosa.2022Frontiers in immunology免费全文
  40. Does time to esophagectomy following neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma affect outcomes?2022Frontiers in immunology免费全文
  41. Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis.2022Frontiers in immunology免费全文
  42. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.2022Frontiers in public health免费全文
  43. Development and validation of a nomogram for preoperative prediction of lymph node metastasis in pathological T1 esophageal squamous cell carcinoma.2022Medicine免费全文
  44. Long non-coding RNA LINC00680 functions as a ceRNA to promote esophageal squamous cell carcinoma progression through the miR-423-5p/PAK6 axis.2022Molecular cancer免费全文
  45. iTRAQ and two-dimensional-LC-MS/MS reveal NAA10 is a potential biomarker in esophageal squamous cell carcinoma.2022Proteomics. Clinical applications
  46. Nomogram for prognosis of patients with esophageal squamous cell cancer after minimally invasive esophagectomy established based on non-textbook outcome.2022Surgical endoscopyRCT
  47. Prognostic Value of Carcinoembryonic Antigen Changes Before and After Operation for Esophageal Squamous Cell Carcinoma.2022World journal of surgery
  48. Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma.2021Clinica chimica acta; international journal of clinical chemistry
  49. Associations of interleukin-4 and interleukin-4 receptor loci with esophageal squamous cell carcinoma susceptibility.2021International immunopharmacology
它在 ClinicalTrials.gov 上的全部试验(任何状态)17
  1. A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer即将招募NCT07788001牵头方III期2026-10 启动
  2. Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC正在招募NCT06601309牵头方II期2024-07 启动
  3. Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC正在招募NCT06510660牵头方II期2024-04 启动
  4. Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy正在招募NCT03734952牵头方不分期2023-05 启动
  5. Tumor Regression Grade As Predictor of Adjuvant Therapy状态不明NCT06710665牵头方2024-10 启动
  6. Postoperative Immune Maintenance Therapy for Esophageal Squamous Cell Carcinoma After Radical Resection状态不明NCT06161909牵头方III期2024-01 启动
  7. Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma状态不明NCT05821452牵头方II期2023-05 启动
  8. Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.进行中,不再招募NCT05176002牵头方I/II期2021-11 启动
  9. Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma已完成NCT04009265牵头方III期2019-08 启动
  10. A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT06010303研究中心II期2023-11 启动
  11. Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma已完成NCT04974047研究中心II期2021-08 启动
  12. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  13. Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study已完成NCT03933449研究中心III期2016-12 启动
  14. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  15. Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)已完成NCT02649361研究中心II期2016-01 启动
  16. Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma已完成NCT02395705研究中心III期2015-06 启动
  17. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma状态不明NCT02611700研究中心III期2015-11 启动
PubMed 以外找到的论文(未计入)33
  1. 112. PREOPERATIVE IMMUNE PROGNOSTIC INDEX PREDICTS PROGNOSIS AND POSTOPERATIVE ADJUVANT CHEMOTHERAPY BENEFITS OF ESOPHAGEAL SQUAMOUS CELL CARCINOMA AFTER MINIMALLY INVASIVE ESOPHAGECTOMY2025Diseases of the Esophagus论文
  2. 136. IDENTIFICATION OF ZINC FINGER PROTEIN-RELATED GENES AS PROGNOSTIC INDICATORS AND PREDICTOR OF IMMUNETHERAPY RESPONSE FOR ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  3. 230. IMPACT OF CLINICAL DECISIONS ON PATIENT OUTCOMES AFTER NEOADJUVANT THERAPY IN LOCALLY ADVANCED RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  4. 231. THE ROLE OF TUMOR REGRESSION GRADE IN PREDICTING THE BENEFIT OF ADJUVANT THERAPY FOLLOWING NEOADJUVANT CHEMOTHERAPY COMBINED WITH IMMUNOTHERAPY2025Diseases of the Esophagus论文
  5. 233. COMPARISON OF POSTOPERATIVE ADJUVANT THERAPY AND SURGERY ALONE IN PATHOLOGICAL N1–2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A MULTI-CENTER RANDOMIZED CONTROLLED TRIAL2025Diseases of the Esophagus论文
  6. 234. THE APPLICATION OF A NOVEL SPLIT TYPE ROBOTIC SYSTEM CARINA™ PLATFORM FOR ESOPHAGEAL SURGERY2025Diseases of the Esophagus论文
  7. 236. SAFETY AND EFFICACY OF CAMRELIZUMAB COMBINED WITH RADIOTHERAPY AS NEOADJUVANT THERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  8. 237. IMPACT OF LYMPH NODE DISSECTION ON PROGNOSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA PATIENTS UNDERGOING NEOADJUVANT CHEMOIMMUNOTHERAPY FOLLOWED BY RADICAL SURGERY2025Diseases of the Esophagus论文
  9. 242. BASELINE 18F-FDG PET/CT SUVMAX AS A PROGNOSTIC INDICATOR FOR LONG-TERM SURVIVAL IN POSTOPERATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  10. 247. BASELINE 18F-FDG PET/CT SUVMAX AS A PROGNOSTIC INDICATOR FOR LONG-TERM SURVIVAL IN POSTOPERATIVE ESOPHAGEAL SQUAMOUS CELL CARCINOMA2025Diseases of the Esophagus论文
  11. 274. INDUCTION THERAPIES FOR LOCALLY ADVANCED MARGINALLY RESECTABLE AND UNRESECTABLE ESCC AND CONVERSION SURGERY PROGNOSIS: A REAL-WORLD STUDY2025Diseases of the Esophagus论文
  12. 326. LYMPH NODE METASTASIS PATTERNS IN T1-T2 ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A NOVEL REGIONAL DIVISION OF LYMPH NODES2025Diseases of the Esophagus论文
  13. Adjuvant Sintilimab Therapy for High-Risk Recurrent Esophageal Squamous Cell Carcinoma after Radical Resection: A Multicenter Randomized Controlled Clinical Trial Protocol2025Research Square预印本
  14. Comparison of different induction therapy for locally advanced marginal resectable and unresectable esophageal squamous cell carcinoma and the prognostic value of subsequent conversion surgery: A real world study.2025Journal of Clinical Oncology论文
  15. Comparison of postoperative adjuvant therapy and surgery alone in pathological N1-2 esophageal squamous cell carcinoma: A prospective multi-center randomized controlled trial.2025Journal of Clinical Oncology会议摘要
  16. Envafolimab combined with albumin-bound paclitaxel and cisplatin in the neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective, single-arm, multicenter phase II study.2025Journal of Clinical Oncology论文
  17. Impact of lymph node dissection on prognosis in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemotherapy and immunotherapy followed by radical surgery.2025Journal of Clinical Oncology论文
  18. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A prospective single-arm phase II clinical trial.2025Journal of Clinical Oncology会议摘要
  19. The application of a novel split-type robotic system, Carina Platform, for esophageal surgery.2025Journal of Clinical Oncology论文
  20. The lost evidence: A phase III, multicenter randomized controlled trial of neoadjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA–IIIB esophageal squamous cell carcinoma.2025Journal of Clinical Oncology会议摘要
  21. Tislelizumab (TIS; BGB-A317) plus chemotherapy (CT)/chemoradiotherapy (CRT) as positron emission tomography (PET)–guided neoadjuvant (n) treatment (tx) for resectable esophageal squamous cell carcinoma (R-ESCC): RATIONALE-213 final analysis2025Journal of Clinical Oncology会议摘要
  22. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncology会议摘要
  23. Tagging polymorphisms in CTLA4 gene with esophageal squamous cell carcinomas: a case-control study2024Research Square预印本
  24. 145P Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)2023Annals of Oncology论文
  25. 20. ADDITIONAL NEOADJUVANT IMMUNOTHERAPY DOESN’T INCREASE THE RISK OF ANASTOMOTIC LEAKAGE AFTER ESOPHAGECTOMY: A MULTICENTER RETROSPECTIVE COHORT STUDY2023Diseases of the Esophagus论文
  26. 325. CAMRELIZUMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CHEMORADIOTHERAPY FOR THE CONVERSION OF UNRESECTABLE ESOPHAGEAL CARCINOMA: A PROSPECTIVE CLINICAL STUDY PROTOCOL2023Diseases of the Esophagus论文
  27. 337. PREDICTION OF PULMONARY METASTASIS IN ESOPHAGEAL CARCINOMA PATIENTS WITH INDETERMINATE2023Diseases of the Esophagus论文
  28. 339. CYTOPLASMIC TRANSLOCATION OF BCLAF1 REGULATES SIX1 MRNA STABILITY THROUGH YTHDF2 TO PROMOTE AEROBIC GLYCOLYSIS IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA2023Diseases of the Esophagus论文
  29. 41. HIGH COMPREHENSIVE COMPLICATION INDEX AFTER MINIMALLY INVASIVE ESOPHAGECTOMY ASSOCIATED WITH POOR SHORT-TERM AND LONG-TERM OUTCOME: A PROPENSITY SCORE MATCHING ANALYSIS2023Diseases of the Esophagus论文
  30. Characteristics of the gut microbiome in patients with Esophageal Squamous Cell Cancer2022Research Square预印本
  31. Concurrent Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma2022International Journal of Radiation Oncology*Biology*Physics论文
  32. Predictive value for advanced lung cancer inflammation index within short- /long-term outcomes of esophageal squamous cell carcinoma after minimally invasive esophagectomy cases: a propensity score matching study2022Research Square预印本
  33. Development of a Prognostic Nomogram and Risk Stratification System for Upper Thoracic Esophageal Squamous Cell Carcinoma2021Research Square预印本

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 47 篇,占 0.3%。

牵头论文
47
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 4420222023: 121220232024: 121220242025: 12122025

福州有 6 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    分期
    I/II期
    开始
    2021-11
    登记号
    NCT05024214

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、哈尔滨、大连、天津、广州、杭州、沈阳、珠海、福州、蚌埠、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫与靶向药物复发与预后影像、人工智能与早期发现
论文中的科室普外/肝胆胰外科影像/核医学科消化/肝病科病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文47
  1. Lactylated SPTAN1 Accelerates Hepatocellular Carcinoma Progression by Promoting NOTCH1/HES1 Activation and Immunosuppression.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  2. Inhibition of RBPJ transcription complex promotes IL-17 and IFN-γ secretion by CD4⁺ T cells in hepatocellular carcinoma.2025Archives of pharmacal research
  3. Can the detection of serum glutathione reductase serve as an effective complement to traditional tumor biomarkers in clinical laboratory medicine for patients with hepatocellular carcinoma?2025BMC cancer免费全文
  4. New mechanistic understanding of FXR agonist Vonafexor: inducing sublethal damage of HBV-positive liver cancer cells via promoting anti-tumor immunity.2025British journal of cancer免费全文
  5. Hepatitis B Virus X Protein Upregulates SREBP2 to Modulate Autophagy in Hepatocellular Carcinoma.2025Cancer medicine免费全文
  6. Efficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus.2025Cardiovascular and interventional radiology
  7. N-glycosylated LTβR increases the Th17/Treg cell ratio in liver cancer by blocking RORC ubiquitination and FOXP3 transcription.2025Cell death & disease免费全文
  8. Intratumoral Brevibacillus parabrevis enhances antitumor immunity by inhibiting NK cell ferroptosis in hepatocellular carcinoma.2025Cell death & disease免费全文
  9. tRNA methyltransferase DNMT2 promotes hepatocellular carcinoma progression and enhances Bortezomib resistance through inhibiting TNFSF10.2025Cellular signalling
  10. TCP1 promotes the progression of malignant tumours by stabilizing c-Myc through the AKT/GSK-3β and ERK signalling pathways.2025Communications biology免费全文
  11. Neurogranin facilitates maintaining the immunosuppressive state of hepatocellular carcinoma by promoting TGF-β1 secretion.2025International journal of biological macromolecules
  12. The Red Cell Distribution Width to Albumin Ratio: A Novel Prognostic Indicator in Hepatitis B Virus-Related Hepatocellular Carcinoma.2025International journal of medical sciences免费全文
  13. Short-term starvation inhibits CD36 N-glycosylation and downregulates USP7 UFMylation to alleviate RBPJ-maintained T cell exhaustion in liver cancer.2025Theranostics免费全文
  14. Hepatitis B virus X protein differentially regulates the angiogenesis of Hepatocellular Carcinoma through p53-VEGF axis according to glucose levels.2024Annals of hepatology
  15. Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.2024BMJ open免费全文
  16. SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma.2024Cellular oncology (Dordrecht, Netherlands)免费全文
  17. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.2024Cellular signalling
  18. YTHDF3-mediated m6A modification of NKD1 regulates hepatocellular carcinoma invasion and metastasis by activating the WNT/β-catenin signaling axis.2024Experimental cell research
  19. The elevated expression of serum glutathione reductase in hepatocellular carcinoma and its role in assessing the therapeutic efficacy and prognosis of transarterial chemoembolization.2024Free radical biology & medicine
  20. Novel prognostic signature for hepatocellular carcinoma using a comprehensive machine learning framework to predict prognosis and guide treatment.2024Frontiers in immunology免费全文
  21. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.2024Frontiers in public health免费全文
  22. Laparoscopic liver resection is superior to radiofrequency ablation for small hepatocellular carcinoma: a systematic review and meta-analysis of propensity score-matched studies.2024Hepatology international
  23. Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability.2024International immunopharmacology
  24. Predictive indicators of immune therapy efficacy in hepatocellular carcinoma based on neutrophil-to-lymphocyte ratio.2024International immunopharmacology
  25. LAIR1 promotes hepatocellular carcinoma cell metastasis and induces M2-macrophage infiltration through activating AKT-IKKβ-p65 axis.2024Molecular carcinogenesis
  26. ASO Author Reflections: The Application of ICG Fluorescent Staining in Laparoscopic Hepatectomy for Liver Malignancies is More Beneficial to Ensure Radical Surgery.2023Annals of surgical oncology
  27. Does Using Indocyanine Green Fluorescence Imaging for Tumors Help in Determining the Safe Surgical Margin in Real-Time Navigation of Laparoscopic Hepatectomy? A Retrospective Study.2023Annals of surgical oncology免费全文
  28. XPO1 intensifies sorafenib resistance by stabilizing acetylation of NPM1 and enhancing epithelial-mesenchymal transition in hepatocellular carcinoma.2023Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  29. Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis.2023Brachytherapy
  30. A modified immune cell infiltration score achieves ideal stratification for CD8+ T cell efficacy and immunotherapy benefit in hepatocellular carcinoma.2023Cancer immunology, immunotherapy : CII免费全文
  31. Transthyretin promotes the invasion of combined hepatocellular cholangiocarcinoma by tumor-associated macrophages.2023Cancer reports (Hoboken, N.J.)免费全文
  32. TGF-β-p-STAT1-LAIR2 axis has a "self-rescue" role for exhausted CD8+ T cells in hepatocellular carcinoma.2023Cellular oncology (Dordrecht, Netherlands)免费全文
  33. Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8+ T cells in hepatocellular carcinoma.2023Communications biology免费全文
  34. Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis.2023Gene
  35. Red Blood Cell Distribution Width as a Potential Valuable Survival Predictor in Hepatitis B Virus-related Hepatocellular Carcinoma.2023International journal of medical sciences免费全文
  36. 2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.2023Journal for immunotherapy of cancer免费全文
  37. SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape.2023Science signaling
  38. Exosomal circGSE1 promotes immune escape of hepatocellular carcinoma by inducing the expansion of regulatory T cells.2022Cancer science免费全文
  39. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.2022Cell biology and toxicology
  40. lncRNA MIAT targets miR-411-5p/STAT3/PD-L1 axis mediating hepatocellular carcinoma immune response.2022International journal of experimental pathology
  41. Evaluation of microvascular invasion of hepatocellular carcinoma using whole-lesion histogram analysis with the stretched-exponential diffusion model.2022The British journal of radiology免费全文
  42. Overexpression of NOP58 as a Prognostic Marker in Hepatocellular Carcinoma: A TCGA Data-Based Analysis.2021Advances in therapy
  43. Clinical characteristics and surgical treatments of primary hepatic angiosarcoma.2021BMC gastroenterology免费全文
  44. Quantification of Intrafraction and Interfraction Tumor Motion Amplitude and Prediction Error for Different Liver Tumor Trajectories in Cyberknife Synchrony Tracking.2021International journal of radiation oncology, biology, physics
  45. c-Src promotes the growth and tumorigenesis of hepatocellular carcinoma via the Hippo signaling pathway.2021Life sciences
  46. The Islanding effect - a special method of percutaneous peritumor ethanol injection for hepatocellular carcinoma: 15-year follow-up outcome.2021Medicine免费全文
  47. Increased effects of 2,5-dimethylcelecoxib on sensitivity of hepatocellular carcinoma cells to sorafenib via CYP3A5 expression and activation of AMPK.2021Toxicology in vitro : an international journal published in association with BIBRA
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Ultra-stable Iodized Oil-Chemo Embolization Seq Thermal Ablation in Early Liver Ca进行中,不再招募NCT07493070牵头方不分期2026-02 启动
  2. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors正在招募NCT05024214研究中心I/II期2021-11 启动
  3. A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC已完成NCT03764293研究中心III期2019-06 启动
  4. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  5. A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)已完成NCT03412773研究中心III期2017-12 启动
  6. A Study to Evaluate SHR-1210 in Subjects With Advanced HCC已完成NCT02989922研究中心II期2016-11 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 166 篇,占 1.7%。

牵头论文
166
2021–2025 年
牵头试验
48
任何状态,ClinicalTrials.gov
牵头的开放试验
12
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 333320212022: 232320222023: 262620232024: 393920242025: 43432025

福州有 6 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 17

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
    分期
    未注明
    开始
    2025-05
    登记号
    NCT06945718

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  2. 正在招募
    A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
    分期
    未注明
    开始
    2023-05
    登记号
    NCT05938309

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  3. 正在招募
    3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer
    分期
    III期
    开始
    2023-01
    登记号
    NCT06161207

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  4. 正在招募
    A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients
    分期
    不分期
    开始
    2023-01
    登记号
    NCT06277024

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  5. 正在招募
    Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer
    分期
    II期
    开始
    2022-06
    登记号
    NCT05618821

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  6. 正在招募
    Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
    分期
    未注明
    开始
    2018-10
    登记号
    NCT03716089

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  7. 即将招募
    Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
    分期
    III期
    开始
    2026-12
    登记号
    NCT07314203

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  8. 即将招募
    the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer
    分期
    不分期
    开始
    2022-02
    登记号
    NCT05235932

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  9. 即将招募
    Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes
    分期
    II期
    开始
    2022-09
    登记号
    NCT05524974

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  10. 即将招募
    Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes
    分期
    III期
    开始
    2022-11
    登记号
    NCT05610332

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  11. 即将招募
    Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer
    分期
    不分期
    开始
    2021-03
    登记号
    NCT04795063

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  12. 邀请入组
    Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
    分期
    早期I期
    开始
    2025-05
    登记号
    NCT07356466

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  13. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  14. 正在招募
    Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
    分期
    不分期
    开始
    2026-06
    登记号
    NCT07552402

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南宁、成都、杭州、武汉、石家庄、福州、苏州、银川

  15. 正在招募
    Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer
    分期
    III期
    开始
    2025-06
    登记号
    NCT07029269

    年龄 18 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心兰州、广州、杭州、福州、西安

  16. 正在招募
    Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
    分期
    未注明
    开始
    2023-01
    登记号
    NCT05722275

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心北京、太原、广州、昆明、福州、郑州

  17. 正在招募
    AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
    分期
    未注明
    开始
    2023-09
    登记号
    NCT06035250

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南宁、天津、广州、昆明、沈阳、福州、苏州、郑州、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题手术化疗与综合治疗腹膜转移与晚期
论文中的科室肿瘤内科影像/核医学科消化/肝病科普外/肝胆胰外科
牵头的论文166
  1. NCAPD2 Modulates MHC-I Antigen Presentation via the PI3K/AKT Axis to Drive Metastatic Progression in Gastric Cancer.2026Digestive diseases and sciences
  2. Identifying chemotherapy benefits in high-risk patients with stage IB gastric cancer based on recurrence prediction value: A multicenter retrospective study.2026European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  3. A Cascaded Segmentation-Classification Deep Learning Framework for Preoperative Prediction of Occult Peritoneal Metastasis and Early Recurrence in Advanced Gastric Cancer.2025Academic radiology
  4. Timing of postoperative chemotherapy and prognosis in neoadjuvant-treated gastric cancer patients: a multicenter real-world cohort study.2025Annals of medicine免费全文
  5. Machine Learning Prediction of Early Recurrence in Gastric Cancer: A Nationwide Real-World Study.2025Annals of surgical oncology
  6. Clinical Value of Nomograms Integrating Circulating Lipid and Inflammation Risk Score in Predicting Long-Term Outcomes After Radical Gastrectomy in Gastric Cancer: A Multicenter Real-World Study.2025Annals of surgical oncology
  7. Effect of Adjuvant Chemotherapy Cycles on Patients with Node-Negative Gastric Cancer Following Neoadjuvant Chemotherapy: Multicenter Cohort Study.2025Annals of surgical oncology
  8. Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping: Chemotherapy, Immunotherapy, or Targeted Therapy?-A Retrospective Analysis.2025Annals of surgical oncology
  9. Appraisal of Residual Tumor Burden on Survival Prognosis Following Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: A Multicenter Cohort Study.2025Annals of surgical oncology
  10. Patterns of Survival and Recurrence in Poor Responders to Neoadjuvant Therapy for Gastric Cancer: A Real-World Multicenter Study.2025Annals of surgical oncology
  11. Effect of Helicobacter pylori infection on survival outcomes of patients undergoing radical gastrectomy after neoadjuvant chemotherapy: a multicenter study in China.2025BMC cancer免费全文
  12. Development and validation of a prognostic prediction model for elderly gastric cancer patients based on oxidative stress biochemical markers.2025BMC cancer免费全文
  13. Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial.2025BMC medicineRCT免费全文
  14. Comparison of gastric microbiota in patients with different gastric lesions in high and low risk areas of gastric cancer.2025BMC microbiology免费全文
  15. Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy.2025Cancer research免费全文
  16. Targeting LHPP in neoadjuvant chemotherapy resistance of gastric cancer: insights from single-cell and multi-omics data on tumor immune microenvironment and stemness characteristics.2025Cell death & disease免费全文
  17. Safety and efficacy of indocyanine green-guided laparoscopic lymphadenectomy for locally advanced gastric cancer: The CLASS-11 clinical trials.2025Cell reports. MedicineRCT免费全文
  18. Koumine alters immune barrier function by targeting TGFβ-mediated collagen deposition in gastric cancer.2025European journal of pharmacology
  19. Development of a modified nutritional index model based on nutritional status and sarcopenia to predict long-term survival and chemotherapy benefits in elderly patients with advanced gastric cancer.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  20. Enhancing prognostic accuracy in gastric cancer: The TNrrM staging system versus the AJCC TNM system.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  21. Comparison of short- and mid-term outcomes of robotic versus laparoscopic gastrectomy in high-risk patients with gastric cancer: a nationwide, multicentre cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  22. Surgical and oncological outcomes of laparoscopic versus open gastrectomy after neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter analysis.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  23. Long-term survival analysis after radical gastrectomy for Epstein-Barr virus-associated gastric cancer: A multicenter study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  24. Dynamic postoperative prognosis and follow-up optimization for gastric cancer patients after neoadjuvant therapy: a multicenter retrospective study.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  25. Paradoxical effects of adiposity and inflammation on immunotherapy efficacy in gastric cancer: novel insights from real-world data.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  26. A novel ypN-TRG staging system for gastric cancer patients after neoadjuvant therapy based on the metro-ticket paradigm: a multicenter and large sample retrospective analysis.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  27. Exploring the role of OSMR in gastric cancer: from oncogenic functions to relevant immune features.2025International immunopharmacology
  28. Assessment of robotic versus laparoscopic gastrectomy for gastric cancer patients with intraoperative technical complexity: a multicenter retrospective study.2025International journal of surgery (London, England)免费全文
  29. Development and validation of a novel modified cancer cachexia index in patients with locally advanced gastric cancer undergoing neoadjuvant chemotherapy: a multicenter cohort study.2025International journal of surgery (London, England)免费全文
  30. Development of a staging system for hepatoid adenocarcinoma of the stomach based on multicenter data: a retrospective cohort study.2025International journal of surgery (London, England)免费全文
  31. Prognostic Impact of Fluorescent Lymphography on Gastric Cancer After Neoadjuvant Chemotherapy.2025JAMA surgery免费全文
  32. The impact of surgical case order on short- and long-term outcomes in patients undergoing laparoscopic gastrectomy: a propensity matched study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  33. Multi-cohort study in gastric cancer to develop CT-based radiomic models to predict pathological response to neoadjuvant immunotherapy.2025Journal of translational medicine免费全文
  34. Trend analysis and projection of gastric cancer burden linked to high sodium intake in China, Japan, Republic of Korea, and Mongolia (1990-2021): A comprehensive assessment based on the 2021 global burden of disease study.2025PloS one免费全文
  35. Trend analysis and projection of the gastric cancer disease burden in Taiwan during 1990-2021: An analysis of the global burden of disease study 2021.2025PloS one免费全文
  36. Long-term trends and projections of stomach cancer burden in China: Insights from the GBD 2021 study.2025PloS one免费全文
  37. Comprehensive comparison of technical performance, surgical outcomes, and oncologic prognosis between remnant gastric cancer and primary upper-third gastric cancer in the era of minimally invasive surgery: A pooled analysis of 3 prospective2025Surgery
  38. The minimum number of lymph node retrieval in gastric cancer patients after neoadjuvant therapy: An international multi-institute cohort study.2025Surgery
  39. Textbook oncological outcome of locally advanced gastric cancer patients with preoperative sarcopenia: a multicenter clinical study.2025Surgical endoscopy
  40. Assessment of the safety and efficacy of robotic versus laparoscopic gastrectomy in overweight patients with gastric cancer: a large-scale multicenter cohort study.2025Surgical endoscopy
  41. Predicting the prognosis of radical gastrectomy for patients with locally advanced gastric cancer after neoadjuvant chemotherapy using machine learning technology: a multicenter study in China.2025Surgical endoscopy
  42. Comparison of short- and long-term outcomes for robotic versus laparoscopic gastrectomy in elderly patients with gastric cancer: a multicenter cohort study.2025Surgical endoscopy
  43. Development of a prognostic oxidative stress-immune-inflammation score and online calculators for predicting survival and recurrence in gastric cancer: a multicenter study.2025Surgical endoscopy
  44. Preoperative visceral fat area predicts intraoperative adverse events during lymphadenectomy in laparoscopic gastrectomy for gastric cancer: a post hoc analysis.2025Surgical endoscopyRCT
  45. Impact of visceral fat distribution on postoperative complications in high-aged patients undergoing gastric cancer surgery: A cross-sectional study.2025World journal of gastroenterology免费全文
  46. Assessment of Laparoscopic Indocyanine Green Tracer-guided Lymphadenectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Controlled Trial.2024Annals of surgeryRCT
  47. Comparison of Short-term and Three-year Oncological Outcomes Between Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Large Multicenter Cohort Study.2024Annals of surgery
  48. Comparison of Short-Term Outcomes After Robotic Versus Laparoscopic Radical Gastrectomy for Advanced Gastric Cancer in Elderly Individuals: A Propensity Score-Matching Study.2024Annals of surgical oncology
  49. Predictive Value of a New Muscle Parameter in Patients with Resectable Gastric Cancer: A Pooled Analysis of Three Prospective Trials.2024Annals of surgical oncology免费全文
  50. Laparoscopic radical gastrectomy for gastric cancer: Long-term outcome in a teaching center.2024Asian journal of surgery
  51. Impact of dynamic changes of tumor marker in neoadjuvant chemotherapy-treated triple-negative gastric cancer patients: a multi-center study.2024BMC cancer免费全文
  52. Trajectories of neutrophil-to-lymphocyte ratios during neoadjuvant chemotherapy correlate with short- and long-term outcomes in gastric cancer: a group-based trajectory analysis.2024BMC cancer免费全文
  53. The diagnostic value of two-dimensional ultrasound Su-RADS combined with shear wave elastography for benign and malignant lesions of the gastric wall.2024BMC medical imaging免费全文
  54. Global incidence and mortality trends of gastric cancer and predicted mortality of gastric cancer by 2035.2024BMC public health免费全文
  55. Increased ONECUT2 induced by Helicobacter pylori promotes gastric cancer cell stemness via an AKT-related pathway.2024Cell death & disease免费全文
  56. NUAK1 activates STAT5/GLI1/SOX2 signaling to enhance cancer cell expansion and drives chemoresistance in gastric cancer.2024Cell reports
  57. Circ-0075305 hinders gastric cancer stem cells by indirectly disrupting TCF4-β-catenin complex and downregulation of SOX9.2024Communications biology免费全文
  58. A Preoperative Prediction Model for Lymph Node Metastasis in Patients with Gastric Cancer Using a Machine Learning-based Ultrasomics Approach.2024Current medical imaging
  59. Risk stratification models incorporating oxidative stress factors to predict survival and recurrence in patients with gastric cancer after radical gastrectomy: A real-world multicenter study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  60. Reply to: Chemotherapy benefits in patients with hepatoid adenocarcinoma: A long-term follow-up study on a rare gastric disease.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  61. Effects of tumor marker regression load score on long-term prognosis of gastric cancer patients undergoing radical surgery after neoadjuvant chemotherapy.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  62. Textbook oncological outcomes and prognosis after curative gastrectomy in advanced gastric cancer: A multicenter study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  63. Prognostic value of preoperative sarcopenia in gastric cancer: A 10-year follow-up study.2024European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  64. Construction of a nomogram with IrAE and clinic character to predict the survival of advanced G/GEJ adenocarcinoma patients undergoing anti-PD-1 treatment.2024Frontiers in immunology免费全文
  65. Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion.2024Frontiers in immunology免费全文
  66. Impact of chemotherapy delay on long-term prognosis of laparoscopic radical surgery for locally advanced gastric cancer: a pooled analysis of four randomized controlled trials.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  67. Long-term oncological outcomes of 3D versus 2D laparoscopic gastrectomy for gastric cancer: a randomized clinical trial.2024Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCT
  68. KLHL21 suppresses gastric tumourigenesis via maintaining STAT3 signalling equilibrium in stomach homoeostasis.2024Gut
  69. Enlightenment of robotic gastrectomy from 527 patients with gastric cancer in the minimally invasive era: 5 years of optimizing surgical performance in a high-volume center - a retrospective cohort study.2024International journal of surgery (London, England)免费全文
  70. The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: a multicentre real-world clinical study.2024International journal of surgery (London, England)免费全文
  71. Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Greater Curvature Invasion: Five-Year Outcomes From the Fuges-02 Randomized Clinical Trial.2024JAMA surgeryRCT免费全文
  72. Exosomes derived from gastric cancer cells promote phenotypic transformation of hepatic stellate cells and affect the malignant behavior of gastric cancer cells.2024Journal of cancer research and therapeutics
  73. Robotic versus laparoscopic distal gastrectomy for resectable gastric cancer: a randomized phase 2 trial.2024Nature communicationsRCT免费全文
  74. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial.2024Nature communicationsRCT免费全文
  75. AKR1C3 mediates gastric cancer cell invasion and metastasis via the AKT and JNK/p-NF-κB signaling pathways.2024Scientific reports免费全文
  76. Novel nomogram and risk stratification for peritoneal recurrence after curative resection in gastric cancer.2024Scientific reports免费全文
  77. Effect of sarcopenia on short-term and long-term outcomes of older patients with locally advanced gastric cancer: a multicenter study.2024Surgical endoscopy
  78. Developing a modified textbook outcome for elderly patients with gastric cancer: a multi-center study.2024Surgical endoscopy
  79. Robotic gastrectomy was reliable option for overweight patients with gastric cancer: a propensity score matching study.2024Surgical endoscopy
  80. Robot-assisted versus laparoscopic-assisted gastrectomy among malnourished patients with gastric cancer based on textbook outcome.2024Surgical endoscopy
  81. Appraisal of surgical outcomes and oncological efficiency of intraoperative adverse events in robotic radical gastrectomy for gastric cancer.2024Surgical endoscopy
  82. BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN/AKT/β-catenin pathway.2024Theranostics免费全文
  83. Comprehensive multi-omics analysis of pyroptosis for optimizing neoadjuvant immunotherapy in patients with gastric cancer.2024Theranostics免费全文
  84. Preoperative prediction of lymphovascular and perineural invasion in gastric cancer using spectral computed tomography imaging and machine learning.2024World journal of gastroenterology免费全文
  85. Loss of ATOH1 in Pit Cell Drives Stemness and Progression of Gastric Adenocarcinoma by Activating AKT/mTOR Signaling through GAS1.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  86. Tumor Immunophenotyping-Derived Signature Identifies Prognosis and Neoadjuvant Immunotherapeutic Responsiveness in Gastric Cancer.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)免费全文
  87. Intraoperative Adverse Events, Technical Performance, and Surgical Outcomes in Laparoscopic Radical Surgery for Gastric Cancer: A Pooled Analysis From 2 Randomized Trials.2023Annals of surgery
  88. Patient-Reported Outcomes of Individuals with Gastric Cancer Undergoing Totally Laparoscopic Versus Laparoscopic-Assisted Total Gastrectomy: A Real-World, Propensity Score-Matching Analysis.2023Annals of surgical oncology
  89. Nomogram to Predict Recurrence and Guide a Pragmatic Surveillance Strategy After Resection of Hepatoid Adenocarcinoma of the Stomach: A Retrospective Multicenter Study.2023Annals of surgical oncology
  90. Value of the Preoperative D-Dimer to Albumin Ratio for Survival and Recurrence Patterns in Gastric Cancer.2023Annals of surgical oncology
  91. ASO Author Reflections: A Recurrence Nomogram to Guide Surveillance Strategies After the Resection of Hepatoid Adenocarcinoma of the Stomach.2023Annals of surgical oncology
  92. Evaluation of dynamic recurrence risk for locally advanced gastric cancer in the clinical setting of adjuvant chemotherapy: a real-world study with IPTW-based conditional recurrence analysis.2023BMC cancer免费全文
  93. CDK5RAP3 acts as a tumour suppressor in gastric cancer through the infiltration and polarization of tumour-associated macrophages.2023Cancer gene therapy免费全文
  94. Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases: A real-world retrospective study.2023Cancer medicine免费全文
  95. Neurotransmitter Receptor HTR2B Regulates Lipid Metabolism to Inhibit Ferroptosis in Gastric Cancer.2023Cancer research
  96. A scoring model for predicting early recurrence of gastric cancer with normal preoperative tumor markers: A multicenter study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  97. Long-term prognostic benefit of adjuvant chemotherapy for patients with hepatoid adenocarcinoma of the stomach after radical resection: A national multicenter study.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  98. The GLIM criteria as an effective tool for survival prediction in gastric cancer patients.2023European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  99. SOX9 Modulates the Transformation of Gastric Stem Cells Through Biased Symmetric Cell Division.2023Gastroenterology免费全文
  100. Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling.2023Gut免费全文
  101. An international multi-institution real-world study of the optimal surveillance frequency for stage II/III gastric cancer: the more, the better?2023International journal of surgery (London, England)RCT免费全文
  102. Assessment of Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Invasion Into the Greater Curvature: A Randomized Clinical Trial.2023JAMA surgery免费全文
  103. Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study from SEER Database.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  104. Delta computed tomography radiomics features-based nomogram predicts long-term efficacy after neoadjuvant chemotherapy in advanced gastric cancer.2023La Radiologia medica
  105. Indocyanine green fluorescence imaging-guided versus conventional laparoscopic lymphadenectomy for gastric cancer: long-term outcomes of a phase 3 randomised clinical trial.2023Nature communicationsRCT免费全文
  106. Short-term outcomes of a new gastrointestinal decompression tube combined with conservative treatment in patients with esophagojejunal anastomotic leakage after total gastrectomy.2023Surgical endoscopy
  107. Comparison of robotic versus laparoscopic versus open distal gastrectomy for locally advanced gastric cancer: a prospective trial-based economic evaluation.2023Surgical endoscopy
  108. Oncological outcomes of laparoscopic versus open radical total gastrectomy for upper-middle gastric cancer after neoadjuvant chemotherapy: a study of real-world data.2023Surgical endoscopy
  109. Silencing Rac1 and Prex1 Inhibit Epithelial-Mesenchymal Transition in Human Gastric Cancer Cells Induced by Transforming Growth Factor-β1.2023The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology免费全文
  110. A Novel ypTLM Staging System Based on LODDS for Gastric Cancer After Neoadjuvant Therapy: Multicenter and Large-Sample Retrospective Study.2023World journal of surgery
  111. Surgical Outcomes, Technical Performance, and Surgery Burden of Robotic Total Gastrectomy for Locally Advanced Gastric Cancer: A Prospective Study.2022Annals of surgery
  112. ASO Author Reflections: Radiomic Immunosuppressive Scoring System for Predicting Prognosis and Chemotherapy Benefit in Gastric Cancer.2022Annals of surgical oncology
  113. Radiographical Evaluation of Tumor Immunosuppressive Microenvironment and Treatment Outcomes in Gastric Cancer: A Retrospective, Multicohort Study.2022Annals of surgical oncology
  114. m6A methylation mediates LHPP acetylation as a tumour aerobic glycolysis suppressor to improve the prognosis of gastric cancer.2022Cell death & disease免费全文
  115. The Therapeutic Effects of Dihydroartemisinin on Cisplatin-Resistant Gastric Cancer Cells.2022Current pharmaceutical biotechnology
  116. Development and validation of metabolic scoring to individually predict prognosis and monitor recurrence early in gastric cancer: A large-sample analysis.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  117. Novel CT based clinical nomogram comparable to radiomics model for identification of occult peritoneal metastasis in advanced gastric cancer.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  118. Textbook outcome, chemotherapy compliance, and prognosis after radical gastrectomy for gastric cancer: A large sample analysis.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  119. A novel hematological classifier predicting chemotherapy benefit and recurrence hazard for locally advanced gastric cancer A multicenter IPTW analysis.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  120. Postoperative follow-up for gastric cancer needs to be individualized according to age, tumour recurrence pattern, and recurrence time.2022European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  121. Body composition parameters for predicting the efficacy of neoadjuvant chemotherapy with immunotherapy for gastric cancer.2022Frontiers in immunology免费全文
  122. Helicobacter pylori-induced RASAL2 Through Activation of Nuclear Factor-κB Promotes Gastric Tumorigenesis via β-catenin Signaling Axis.2022Gastroenterology免费全文
  123. Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.2022JAMA network open免费全文
  124. Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.2022JAMA surgeryRCT免费全文
  125. Application of an artificial neural network for predicting the potential chemotherapy benefit of patients with gastric cancer after radical surgery.2022SurgeryRCT
  126. Assessment of the short-term outcomes of laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A prospective single-armed clinical trial.2022Surgery
  127. Potential survival benefits of open over laparoscopic radical gastrectomy for gastric cancer patients beyond three years after surgery: result from multicenter in-depth analysis based on propensity matching.2022Surgical endoscopy免费全文
  128. A good preoperative immune prognostic index is predictive of better long-term outcomes after laparoscopic gastrectomy compared with open gastrectomy for stage II gastric cancer in elderly patients.2022Surgical endoscopy
  129. A matched cohort study of the failure pattern after laparoscopic and open gastrectomy for locally advanced gastric cancer: does the operative approach matter?2022Surgical endoscopy
  130. Comparison of long-term outcomes after robotic versus laparoscopic radical gastrectomy: a propensity score-matching study.2022Surgical endoscopy
  131. Robotic spleen-preserving total gastrectomy shows better short-term advantages: a comparative study with laparoscopic surgery.2022Surgical endoscopy
  132. Reciprocity between lymphadenectomy quality and adjuvant chemotherapy compliance in gastric cancer: post hoc analysis of two randomized controlled trials.2022Surgical endoscopy
  133. The peroxisome proliferator-activated receptor agonist rosiglitazone specifically represses tumour metastatic potential in chromatin inaccessibility-mediated FABP4-deficient gastric cancer.2022Theranostics免费全文
  134. Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial.2021Annals of surgeryRCT
  135. Fibrinogen-Albumin Ratio as a New Promising Preoperative Biochemical Marker for Predicting Oncological Outcomes in Gastric Cancer: A Multi-institutional Study.2021Annals of surgical oncology
  136. ASO Author Reflections: Fibrinogen-Albumin Ratio as New Promising Biochemical Marker for Predicting Oncological Outcomes in Gastric Cancer Compared with the Combination of Other Inflammation-Related Factors.2021Annals of surgical oncology
  137. Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study.2021Annals of surgical oncology
  138. ASO Author Reflections: Long-Term Efficacy of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer.2021Annals of surgical oncology
  139. BMI-adjusted prognosis of signet ring cell carcinoma in patients undergoing radical gastrectomy for gastric adenocarcinoma.2021Asian journal of surgery
  140. Comparison of submucosal and subserosal approaches toward optimized indocyanine green tracer-guided laparoscopic lymphadenectomy for patients with gastric cancer (FUGES-019): a randomized controlled trial.2021BMC medicineRCT免费全文
  141. Identification of Genes Universally Differentially Expressed in Gastric Cancer.2021BioMed research international免费全文
  142. Perioperative CRP: A novel inflammation-based classification in gastric cancer for recurrence and chemotherapy benefit.2021Cancer medicineRCT免费全文
  143. Effect of Preoperative Tumor Under-Staging on the Long-term Survival of Patients Undergoing Radical Gastrectomy for Gastric Cancer.2021Cancer research and treatment免费全文
  144. Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study.2021Clinical nutrition (Edinburgh, Scotland)
  145. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.2021Current pharmaceutical biotechnology
  146. CT-based radiomics nomogram for preoperative prediction of No.10 lymph nodes metastasis in advanced proximal gastric cancer.2021European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  147. Safety and Efficacy of Camrelizumab in Combination With Nab-Paclitaxel Plus S-1 for the Treatment of Gastric Cancer With Serosal Invasion.2021Frontiers in immunology免费全文
  148. Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  149. Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  150. Reappraise role of No. 10 lymphadenectomy for proximal gastric cancer in the era of minimal invasive surgery during total gastrectomy: a pooled analysis of 4 prospective trial.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  151. LINC00200 contributes to the chemoresistance to oxaliplatin of gastric cancer cells via regulating E2F1/RAD51 axis.2021Human cell
  152. Bioinformatics analysis of the prognosis and biological significance of VCAN in gastric cancer.2021Immunity, inflammation and disease免费全文
  153. PD-1 inhibitor combined with apatinib modulate the tumor microenvironment and potentiate anti-tumor effect in mice bearing gastric cancer.2021International immunopharmacology
  154. Clinical implications of Indocyanine Green Fluorescence Imaging-Guided laparoscopic lymphadenectomy for patients with gastric cancer: A cohort study from two randomized, controlled trials using individual patient data.2021International journal of surgery (London, England)RCT
  155. Outcomes of Laparoscopic Total Gastrectomy Combined With Spleen-Preserving Hilar Lymphadenectomy for Locally Advanced Proximal Gastric Cancer: A Nonrandomized Clinical Trial.2021JAMA network open免费全文
  156. Assessment of Clinicopathological Characteristics and Development of an Individualized Prognostic Model for Patients With Hepatoid Adenocarcinoma of the Stomach.2021JAMA network open免费全文
  157. Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer.2021JAMA network open免费全文
  158. Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer: A Nonrandomized Controlled Trial.2021JAMA network open免费全文
  159. KMT2D promotes proliferation of gastric cancer cells: evidence from ctDNA sequencing.2021Journal of clinical laboratory analysis免费全文
  160. 5-Lipoxygenase promotes epithelial-mesenchymal transition through the ERK signaling pathway in gastric cancer.2021Journal of gastroenterology and hepatology
  161. Increased CD44 Expression and MEK Activity Predict Worse Prognosis in Gastric Adenocarcinoma Patients Undergoing Gastrectomy.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  162. Dynamic Changes in Pre- and Postoperative Levels of Inflammatory Markers and Their Effects on the Prognosis of Patients with Gastric Cancer.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract免费全文
  163. ADP ribosylation factor guanylate kinase 1 promotes the malignant phenotype of gastric cancer by regulating focal adhesion kinase activation.2021Life sciences
  164. Does three-dimensional surgery affect recurrence patterns in patients with gastric cancer after laparoscopic R0 gastrectomy? Results from a 3-year follow-up phase III trial.2021Surgical endoscopyRCT
  165. Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopic-assisted and open radical gastrectomy for gastric cancer - A propensity score-matching analysis.2021Surgical oncology
  166. Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study.2021The oncologist免费全文
中文论文(未计入)8
  1. [Prognostic significance of textbook outcome in advanced gastric patients who underwent neoadjuvant chemotherapy followed by surgical resection].2024Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Quality control of gastric resection range in laparoscopic locally advanced gastric cancer].2024Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Prevention and management of complications related to laparoscopic spleen-preserving hilar lymph node dissection for gastric cancer].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [Effect of splenic hilar lymphadenectomy on locally advanced Siewert type Ⅱ and Ⅲ adenocarcinoma of esophagogastric junction with a tumor diameter ≥4 cm: a five-year survival analysis].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  5. [Analysis of characteristics and trends of randomized controlled trials of gastric cancer between 2000 and 2019].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
  6. [Quality of life after totally laparoscopic versus laparoscopic-assisted total gastrectomy: a retrospective cohort study with propensity score matching].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Technical difficulties and countermeasures of digestive tract reconstruction in robotic radical gastrectomy for gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Establishment of artificial neural network model for predicting lymph node metastasis in patients with stage Ⅱ-Ⅲ gastric cancer].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgeryRCT
它在 ClinicalTrials.gov 上的全部试验(任何状态)73
  1. Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer即将招募NCT07314203牵头方(推断)III期2026-12 启动
  2. Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma邀请入组NCT07356466牵头方(推断)早期I期2025-05 启动
  3. Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)正在招募NCT06945718牵头方(推断)2025-05 启动
  4. 3D-4K-ICG Laparoscopic Gastrectomy for Gastric Cancer正在招募NCT06161207牵头方(推断)III期2023-01 启动
  5. A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors正在招募NCT05938309牵头方(推断)2023-05 启动
  6. A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of HER2 Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients正在招募NCT06277024牵头方(推断)不分期2023-01 启动
  7. Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes即将招募NCT05524974牵头方(推断)II期2022-09 启动
  8. Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Remnant Gastric Cancer正在招募NCT05618821牵头方(推断)II期2022-06 启动
  9. the Clinical Efficacy of Robotic and Laparoscopic Radical Total Gastrectomy in Locally Advanced Middle and Upper Gastric Cancer即将招募NCT05235932牵头方(推断)不分期2022-02 启动
  10. Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes即将招募NCT05610332牵头方(推断)III期2022-11 启动
  11. Total Robotic Versus Robotic Assisted Distal Gastrectomy for Gastric Cancer即将招募NCT04795063牵头方(推断)不分期2021-03 启动
  12. Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site正在招募NCT03716089牵头方(推断)2018-10 启动
  13. Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy进行中,不再招募NCT06938139牵头方(推断)2025-03 启动
  14. Model for Prognosis of Elderly Gastric Cancer Patients已完成NCT06393153牵头方(推断)2024-01 启动
  15. Prediction Model for Advanced Gastric Cancer in Elderly已完成NCT06467591牵头方(推断)2024-01 启动
  16. Trajectory of Body Composition Identifies LAGC with Cachexia Following NACT已完成NCT06716593牵头方(推断)2024-09 启动
  17. Impact of TTC Following Neoadjuvant Chemotherapy on the Prognosis of LAGC已完成NCT06696963牵头方(推断)2024-03 启动
  18. Hematological Dynamic Scores for Predicting Survival and Treatment Response for Advanced Gastric Cancer After Neoadjuvant Therapy已完成NCT06573307牵头方(推断)2024-06 启动
  19. A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma已完成NCT06337266牵头方(推断)2023-01 启动
  20. Appraisal of the Modified Cancer Cachexia Index in Locally Advanced Gastric Cancer Patients Undergoing Neoadjuvant Chemotherapy已完成NCT06689462牵头方(推断)2023-12 启动
  21. Predict 5-Year Survival in Elderly Gastric Cancer已完成NCT06208046牵头方(推断)2023-07 启动
  22. Effect of Adjuvant Chemotherapy Cycles on Patients With Node-negative Gastric Cancer Following Neoadjuvant Chemotherapy状态不明NCT06277453牵头方(推断)2023-01 启动
  23. Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk已完成NCT06337279牵头方(推断)2022-12 启动
  24. Neoadjuvant Treatment Based on Gastric Cancer Molecular Subtyping.已完成NCT06376773牵头方(推断)2022-06 启动
  25. Questionnaire Survey of the Advanced Training Program for Laparoscopic Radical Gastrectomy已完成NCT05219539牵头方(推断)2021-11 启动
  26. Effect of Gastric Cancer Specialist Training Program in Laparoscopic Gastric Cancer Surgery(STP-LRG-1)已完成NCT05585437牵头方(推断)2021-11 启动
  27. Indocyanine Green Tracer Using in Laparoscopic Radical Gastrectomy for Locally Advanced Gastric Cancer进行中,不再招募NCT04593615牵头方(推断)不分期2020-11 启动
  28. Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer已完成NCT04195828牵头方(推断)II期2020-06 启动
  29. Trials Comparing of HD Versus 4K Laparoscopy for Gastric Cancer状态不明NCT04010006牵头方(推断)不分期2019-07 启动
  30. The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer状态不明NCT06235164牵头方(推断)2019-01 启动
  31. Clinical Efficacy Between Robotic and Laparoscopic Total Gastrectomy in Patients With Clinical Stage I Gastric Cancer状态不明NCT03524300牵头方(推断)不分期2018-06 启动
  32. The Effect of Postoperative Referred Pain in the Left Shoulder on Short-term Outcomes for Laparoscopic Gastrectomy状态不明NCT03482609牵头方(推断)2018-07 启动
  33. Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.已完成NCT06706466牵头方(推断)2018-01 启动
  34. Robotic Total Gastrectomy for Locally Advanced Proximal Gastric Cancer已完成NCT03524287牵头方(推断)不分期2018-03 启动
  35. Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer状态不明NCT03192735牵头方(推断)II期2017-09 启动
  36. Clinical Outcomes of Laparoscopic D1 Versus D2 Lymphadenectomy for Elderly Patients With Advanced Gastric Cancer状态不明NCT03290209牵头方(推断)II期2017-08 启动
  37. Clinical Outcomes of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer已完成NCT03313700牵头方(推断)不分期2017-09 启动
  38. Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection已完成NCT03050879牵头方(推断)II期2017-10 启动
  39. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer状态不明NCT02845986牵头方(推断)II期2016-09 启动
  40. The Safety, Feasibility and Oncological Outcomes of Laparoscopic Completion Total Gastrectomy for Remnant Gastric Cancer状态不明NCT02792881牵头方(推断)不分期2016-06 启动
  41. The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy状态不明NCT02930278牵头方(推断)2016-09 启动
  42. Assessment of Robotic Versus Laparoscopic Gastrectomy for GC Patients With Intraoperative Technical Complexity已完成NCT06752538牵头方(推断)2016-08 启动
  43. Learning Curve and Optimization of Robotic Gastrectomy已完成NCT05715775牵头方(推断)2016-08 启动
  44. The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy状态不明NCT02930291牵头方(推断)2016-09 启动
  45. Prospective Study on Modified Delta-shaped Gastroduodenostomy in Totally Laparoscopic Surgery for Distal Gastric Cancer状态不明NCT02289183牵头方(推断)不分期2015-01 启动
  46. Potential Advantages of Robotic Total Gastrectomy in Advanced Middle-Upper Gastric Cancer: A Multicenter Propensity Score Matching Analysis已完成NCT06941168牵头方(推断)2015-01 启动
  47. Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer状态不明NCT02333721牵头方(推断)不分期2015-01 启动
  48. A Recurrence Nomogram for Hepatoid Adenocarcinoma of the Stomach已完成NCT05274464牵头方(推断)2004-04 启动
  49. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  50. Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer正在招募NCT07552402研究中心不分期2026-06 启动
  51. Feasibility of Enhanced Recovery After Surgery Without Prophylactic Abdominal Drainage Tubes After Laparoscopic Distal Gastrectomy For Gastric Cancer正在招募NCT07029269研究中心III期2025-06 启动
  52. AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy正在招募NCT06035250研究中心2023-09 启动
  53. Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics正在招募NCT05722275研究中心2023-01 启动
  54. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China状态不明NCT05638269研究中心2022-03 启动
  55. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression已完成NCT05052801研究中心III期2022-03 启动
  56. Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer已终止NCT05149807研究中心II/III期2022-01 启动
  57. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.已终止NCT05111626研究中心III期2022-03 启动
  58. Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations状态不明NCT05019794研究中心II期2020-05 启动
  59. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  60. Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901已完成NCT04805307研究中心I期2020-12 启动
  61. Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection进行中,不再招募NCT04581473研究中心I/II期2020-10 启动
  62. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  63. A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma or Gastric/Gastroesophageal Junction Cancer已完成NCT03941873研究中心I/II期2019-02 启动
  64. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)已完成NCT03675737研究中心III期2018-11 启动
  65. Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers状态不明NCT03468712研究中心不分期2018-03 启动
  66. Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)-China Extension已撤回NCT04859582研究中心III期2018-11 启动
  67. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer状态不明NCT03273920研究中心不分期2017-09 启动
  68. Incidence of Pancreatic Fistula After Radical Gastrectomy状态不明NCT03391687研究中心2017-12 启动
  69. A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer已完成NCT02898077研究中心III期2017-03 启动
  70. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC状态不明NCT02915432研究中心I/II期2016-12 启动
  71. A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer已完成NCT02178956研究中心III期2014-10 启动
  72. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer已完成NCT01839500研究中心2013-04 启动
  73. Multicenter Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer (CLASS-01)状态不明NCT01609309研究中心III期2012-09 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年没有牵头骨肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 13 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. USP17 is upregulated in osteosarcoma and promotes cell proliferation, metastasis, and epithelial-mesenchymal transition through stabilizing SMAD4.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 2.5%。

牵头论文
13
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
2
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 2220222023: 4420232024: 4420242025: 222025

福州有 6 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
    分期
    未注明
    开始
    2023-05
    登记号
    NCT05938309

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

  2. 正在招募
    Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
    分期
    未注明
    开始
    2018-10
    登记号
    NCT03716089

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:福建医科大学附属协和医院福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室影像/核医学科普外/肝胆胰外科
牵头的论文13
  1. Treatment research after failure of fourth-line standard therapy for advanced gastrointestinal stromal tumors: A review.2025Cancer
  2. Radiomics models with baseline MRI and clinical data to predict target therapy response and high-risk mortality in metastatic GIST.2025Scientific reports
  3. Feasibility and efficacy of minimally invasive limited resection for primary duodenal gastrointestinal stromal tumors: a retrospective cohort study.2024BMC surgery
  4. Reply to comment on predicting the risk stratification of gastrointestinal stromal tumors using machine learning‑based ultrasound radiomics.2024Journal of medical ultrasonics (2001)
  5. Predicting the risk stratification of gastrointestinal stromal tumors using machine learning-based ultrasound radiomics.2024Journal of medical ultrasonics (2001)
  6. Deep Learning-Based Segmentation and Risk Stratification for Gastrointestinal Stromal Tumors in Transabdominal Ultrasound Imaging.2024Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  7. Panniculitis during avapritinib therapy for gastrointestinal stromal tumour.2023European journal of dermatology : EJD
  8. Prediction of the mitotic index and preoperative risk stratification of gastrointestinal stromal tumors with CT radiomic features.2023La Radiologia medicaRCT
  9. Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.2023The oncologist
  10. Use of a Convolutional Neural Network to Predict the Malignant Potential of Gastrointestinal Stromal Tumors in Transabdominal Ultrasound Images: Visualization of the Focus of the Prediction Model.2023Ultrasound in medicine & biology
  11. Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features.2022La Radiologia medicaRCT
  12. Application of ultrasonography in predicting the biological risk of gastrointestinal stromal tumors.2022Scandinavian journal of gastroenterology
  13. Dynamic survival analysis of gastrointestinal stromal tumors (GISTs): a 10-year follow-up based on conditional survival.2021BMC cancer
中文论文(未计入)1
  1. [Optimal duration of preoperative imatinib therapy in locally advanced gastrointestinal stromal tumors].2025Zhonghua zhong liu za zhi [Chinese journal of oncology]
早期论文(2016–2020 年)4
  1. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.2017Journal of cancer research and clinical oncology
  2. Can laparoscopic surgery be applied in gastric gastrointestinal stromal tumors located in unfavorable sites?: A study based on the NCCN guidelines.2017Medicine
  3. Short- and Long-Term Outcomes of Laparoscopic Versus Open Resection for Gastric Gastrointestinal Stromal Tumors: A Propensity Score-Matching Analysis.2016Medicine
  4. [Impact of laparoscopic surgery on efficacy in the treatment of gastrointestinal stromal tumors in different anatomical locations].2016Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST即将招募NCT05970900牵头方III期2023-10 启动
  2. A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors正在招募NCT05938309牵头方(推断)2023-05 启动
  3. Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site正在招募NCT03716089牵头方(推断)2018-10 启动
  4. A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib已完成NCT04633122研究中心II期2020-11 启动
  5. A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor已完成NCT04254939研究中心I/II期2019-08 启动
  6. (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST已完成NCT03465722研究中心III期2018-03 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.09%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

福州有 9 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 0.4%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
5
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 332025

福州有 2 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

这家医院参与的开放试验 5

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
    分期
    IV期
    开始
    2022-03
    登记号
    NCT05201781

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安

  2. 正在招募
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    分期
    III期
    开始
    2022-10
    登记号
    NCT05552222

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 29 家列出的医院为研究中心上海、北京、南京、南宁、南昌、厦门、哈尔滨、天津、常州、广州、成都、杭州、武汉、沈阳、济南、深圳、温州、福州、西安、郑州、重庆、长春、长沙

  3. 正在招募
    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
    分期
    III期
    开始
    2022-11
    登记号
    NCT05623020

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南京、天津、广州、杭州、武汉、温州、福州、苏州、长春

  4. 正在招募
    A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
    分期
    I/II期
    开始
    2021-09
    登记号
    NCT04973605

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 19 家列出的医院为研究中心上海、北京、南京、南昌、厦门、天津、杭州、武汉、沈阳、石家庄、福州、郑州、重庆、长沙、青岛

  5. 正在招募
    A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
    分期
    III期
    开始
    2021-10
    登记号
    NCT05020236

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心北京、南京、南昌、天津、广州、徐州、杭州、武汉、济南、深圳、温州、石家庄、福州、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题双抗与抗体药物干细胞移植复发与耐药
牵头的论文6
  1. Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation.2026Journal of chemotherapy (Florence, Italy)
  2. USP4, Transcriptionally Activated by MEF2A, Protects Multiple Myeloma Cells From Endoplasmic Reticulum Stress-Mediated Apoptosis via Repressing NR4A1 Ubiquitination.2025FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  3. BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.2025Journal of hematology & oncology免费全文
  4. Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.2025Scientific reports免费全文
  5. Efficacy and safety of tandem autologous stem cell transplantation in multiple myeloma: a retrospective single-center analysis.2023Chinese medical journal免费全文
  6. Modified Culture System and Combination of FICTION Could Increase the Detection Rate of Abnormalities in Multiple Myeloma.2021Annals of clinical and laboratory science
中文论文(未计入)3
  1. [The Value of T Cell subsets and Cytokine Levels Changes in the Clinical Diagnosis, Treatment and Prognosis Evaluation of Multiple Myeloma].2022Zhongguo shi yan xue ye xue za zhi
  2. [Effect of miR-203/CREB1 Signaling Regulation Mediated by DNA Methylation on the Proliferation and Apoptosis of Multiple Myeloma Cells].2022Zhongguo shi yan xue ye xue za zhi
  3. [Expression and Clinical Significance of Heat Shock Protein 90 in Multiple Myeloma Patients].2021Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
  1. A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant正在招募NCT05623020研究中心III期2022-11 启动
  2. A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel正在招募NCT05201781研究中心IV期2022-03 启动
  3. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma正在招募NCT05552222研究中心III期2022-10 启动
  4. A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma正在招募NCT04973605研究中心I/II期2021-09 启动
  5. A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments正在招募NCT05020236研究中心III期2021-10 启动
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide进行中,不再招募NCT06208150研究中心III期2024-01 启动
  7. Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT06158841研究中心III期2024-05 启动
  8. A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05572515研究中心III期2023-03 启动
  9. A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment进行中,不再招募NCT05455320研究中心III期2022-10 启动
  10. A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.已完成NCT05228470研究中心II期2021-12 启动
  11. A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma进行中,不再招募NCT05083169研究中心III期2021-10 启动
  12. A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已终止NCT03758417研究中心II期2019-01 启动
  13. TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03860038研究中心II期2019-01 启动
  14. TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma已完成NCT03952091研究中心III期2019-03 启动
  15. A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)已完成NCT03217812研究中心III期2017-11 启动
  16. Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma已完成NCT03029234研究中心III期2017-03 启动
  17. A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma已完成NCT03234972研究中心III期2017-11 启动
  18. Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma已完成NCT01818752研究中心III期2013-07 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

B 细胞急性淋巴细胞白血病

B-cell acute lymphoblastic leukaemia

2021–2025 年中国大陆作者发表的 225 篇B 细胞急性淋巴细胞白血病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.8%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

福州有 2 家医院列在B 细胞急性淋巴细胞白血病下全国有 90 家医院列在B 细胞急性淋巴细胞白血病下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-01
    登记号
    NCT06764238

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 24 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、深圳、福州、苏州、西安、贵阳、重庆、长沙、青岛

  2. 正在招募
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    分期
    II/III期
    开始
    2025-03
    登记号
    NCT06882057

    年龄 1 岁 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 23 家列出的医院为研究中心上海、南京、南宁、南昌、合肥、天津、广州、成都、武汉、济南、福州、苏州、西安、贵阳、重庆、长沙、青岛

  3. 正在招募
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    分期
    III期
    开始
    2025-03
    登记号
    NCT07152041

    年龄 1 个月 至 18 岁(登记的条件)

    牵头:中国医学科学院血液病医院(血液学研究所);另有 20 家列出的医院为研究中心上海、南京、南昌、天津、广州、成都、武汉、济南、深圳、福州、苏州、贵阳、重庆、长沙、青岛

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题费城染色体与遗传学儿童
论文中的科室儿科
牵头的论文4
  1. UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia.2025Cell death & disease免费全文
  2. Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review.2025Pharmacogenetics and genomics免费全文
  3. Long Non-Coding RNA RP11-252C15.1 Is a Potential Biomarker of Prognosis and Hallmark for Leukemogenesis in Children with B-Cell Precursor Acute Lymphoblastic Leukemia.2024Acta haematologica
  4. Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia.2024BMC cancer免费全文
中文论文(未计入)2
  1. [Clinical Characteristics and Prognosis of Children with Hypodiploid B-cell Precursor Acute Lymphoblastic Leukemia].2024Zhongguo shi yan xue ye xue za zhi
  2. [Clinical Features and Prognosis of Acute T-cell Lymphoblastic Leukemia in Children--Multi-Center Data Analysis in Fujian].2024Zhongguo shi yan xue ye xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
  1. CART-19 Cells For R/R B-ALL状态不明NCT03391739牵头方(推断)II/III期2016-01 启动
  2. Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol正在招募NCT06764238研究中心II/III期2025-01 启动
  3. Newly-diagnosed Pediatric Ph-positive B-ALL Protocol正在招募NCT07152041研究中心III期2025-03 启动
  4. Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol正在招募NCT06882057研究中心II/III期2025-03 启动
  5. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL进行中,不再招募NCT04521231研究中心I/II期2021-01 启动
  6. Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)已完成NCT03476239研究中心III期2017-10 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

再生障碍性贫血

Aplastic anaemia

2021–2025 年中国大陆作者发表的 412 篇再生障碍性贫血 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.5%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

福州有 2 家医院列在再生障碍性贫血下全国有 63 家医院列在再生障碍性贫血下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的再生障碍性贫血开放试验。

这些数字背后的记录
研究主题克隆演变与 PNH
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 6 篇,占 2.2%。

牵头论文
6
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 3320242025: 222025

福州有 3 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
    分期
    III期
    开始
    2026-04
    登记号
    NCT07416604

    年龄 12 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心北京、天津、广州、福州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室病理/检验科

这些论文过半是实验室或动物研究。

牵头的论文6
  1. Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia.2025Annals of hematology
  2. Development and validation of an innovative approach to estimating FVIII levels and designing personalised doses in the prophylactic treatment of haemophilia A: based on the principle of the two-compartment model.2025BMJ open
  3. Chemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.2024International immunopharmacology
  4. Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice.2024International immunopharmacology
  5. Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors.2024Journal of thrombosis and haemostasis : JTH
  6. Hemophilia a patients with inhibitors: Mechanistic insights and novel therapeutic implications.2022Frontiers in immunology
中文论文(未计入)2
  1. [RNA Sequencing Reveals Molecular Alternations of Splenocytes Associated with Anti-FⅧ Immune Response in Hemophilia A Murine Model].2025Zhongguo shi yan xue ye xue za zhi
  2. [Analysis of APTT Mixing Test Results in Factor Ⅷ Inhibitor-Positive Hemophilia Patients].2023Zhongguo shi yan xue ye xue za zhi
早期论文(2016–2020 年)3
  1. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.2017Journal of thrombosis and haemostasis : JTH
  2. The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.2016Blood
  3. [Pathogenetic mechanism for a female patient with hemophilia A].2016Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
它在 ClinicalTrials.gov 上的全部试验(任何状态)11
  1. A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A正在招募NCT07416604研究中心III期2026-04 启动
  2. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.进行中,不再招募NCT07684898研究中心III期2026-06 启动
  3. Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment进行中,不再招募NCT07663903研究中心III期2026-04 启动
  4. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products已完成NCT06738485研究中心III期2025-01 启动
  5. A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A已完成NCT05707351研究中心III期2023-03 启动
  6. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein已完成NCT06142552研究中心III期2023-12 启动
  7. Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)已完成NCT05082116研究中心III期2021-09 启动
  8. An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.已完成NCT04456387研究中心III期2020-10 启动
  9. A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection状态不明NCT03747653研究中心2019-03 启动
  10. Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.状态不明NCT04061109研究中心III期2019-05 启动
  11. China ADVATE PTP Study已完成NCT02170402研究中心IV期2014-06 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

福州有 1 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。

这些数字背后的记录
论文中的科室肾内科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

范可尼贫血

Fanconi anaemia

2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

福州有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。

这些数字背后的记录
论文中的科室肿瘤内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年没有牵头重症肌无力的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

福州有 2 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    分期
    III期
    开始
    2021-07
    登记号
    NCT04951622

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、天津、广州、成都、杭州、济南、福州、西安、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

烟雾病

Moyamoya disease

2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.1%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 2220232024: 0020242025: 112025

福州有 1 家医院列在烟雾病下全国有 47 家医院列在烟雾病下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的烟雾病开放试验。

这些数字背后的记录
研究主题影像与脑血流血管重建手术儿童
论文中的科室神经外科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

抗 NMDA 受体脑炎

Anti-NMDA receptor encephalitis

2021–2025 年没有牵头抗 NMDA 受体脑炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 2 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.4%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

福州有 4 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肺淋巴管平滑肌瘤病

Lymphangioleiomyomatosis

2021–2025 年中国大陆作者发表的 45 篇肺淋巴管平滑肌瘤病 PubMed 英文论文中,这家医院牵头了 1 篇,占 2.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

福州有 1 家医院列在肺淋巴管平滑肌瘤病下全国有 28 家医院列在肺淋巴管平滑肌瘤病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肺淋巴管平滑肌瘤病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肌萎缩侧索硬化症

Amyotrophic lateral sclerosis

2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 11 篇,占 1.4%。

牵头论文
11
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 4420212022: 1120222023: 1120232024: 2220242025: 332025

福州有 5 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。

这些数字背后的记录
论文中的科室影像/核医学科神经内科
牵头的论文11
  1. Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis.2025Annals of medicine
  2. Structural atrophy and functional disturbance in the thalamic nuclei of patients with amyotrophic lateral sclerosis.2025Brain research bulletin
  3. Soma and neurite density imaging detects brain microstructural impairments in amyotrophic lateral sclerosis.2025European journal of radiology
  4. Neurite orientation dispersion and density imaging quantifies microstructural impairment in the thalamus and its connectivity in amyotrophic lateral sclerosis.2024CNS neuroscience & therapeutics
  5. Eomesodermin expression in CD4+T-cells associated with disease progression in amyotrophic lateral sclerosis.2024CNS neuroscience & therapeutics
  6. Corticospinal fibers with different origins impair in amyotrophic lateral sclerosis: A neurite orientation dispersion and density imaging study.2023CNS neuroscience & therapeutics
  7. Characterizing Sensorimotor-Related Area Abnormalities in Amyotrophic Lateral Sclerosis: An Intravoxel Incoherent Motion Magnetic Resonance Imaging Study.2022Academic radiology
  8. Novel FUS mutation Y526F causing rapidly progressive familial amyotrophic lateral sclerosis.2021Amyotrophic lateral sclerosis & frontotemporal degeneration
  9. Dynamic Changes in Functional Network Connectivity Involving Amyotrophic Lateral Sclerosis and Its Correlation With Disease Severity.2021Journal of magnetic resonance imaging : JMRI
  10. White matter microstructural impairments in amyotrophic lateral sclerosis: A mean apparent propagator MRI study.2021NeuroImage. Clinical
  11. Novel TARDBP missense mutation caused familial amyotrophic lateral sclerosis with frontotemporal dementia and parkinsonism.2021Neurobiology of aging
早期论文(2016–2020 年)9
  1. Brain Cortical Complexity Alteration in Amyotrophic Lateral Sclerosis: A Preliminary Fractal Dimensionality Study.2020BioMed research international
  2. Abnormal cerebral microstructures revealed by diffusion kurtosis imaging in amyotrophic lateral sclerosis.2020Journal of magnetic resonance imaging : JMRI
  3. Familial flail leg ALS caused by PFN1 mutation.2020Journal of neurology, neurosurgery, and psychiatry
  4. Novel mutation in optineurin causing aggressive ALS+/-frontotemporal dementia.2019Annals of clinical and translational neurology
  5. Brain white matter abnormalities and correlation with severity in amyotrophic lateral sclerosis: An atlas-based diffusion tensor imaging study.2019Journal of the neurological sciences
  6. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis.2017Journal of neurology, neurosurgery, and psychiatry
  7. H46R SOD1 mutation is consistently associated with a relatively benign form of amyotrophic lateral sclerosis with slow progression.2016Amyotrophic lateral sclerosis & frontotemporal degeneration
  8. Mutations in FUS are the most frequent genetic cause in juvenile sporadic ALS patients of Chinese origin.2016Amyotrophic lateral sclerosis & frontotemporal degeneration
  9. The distinctive genetic architecture of ALS in mainland China.2016Journal of neurology, neurosurgery, and psychiatry
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS即将招募NCT07169175研究中心I/II期2025-12 启动
  2. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis即将招募NCT06645197研究中心早期I期2024-10 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

脊髓性肌萎缩症

Spinal muscular atrophy

2021–2025 年没有牵头脊髓性肌萎缩症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 2 家医院列在脊髓性肌萎缩症下全国有 51 家医院列在脊髓性肌萎缩症下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊髓性肌萎缩症开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Antisense Oligonucleotide for Spinal Muscular Atrophy状态不明NCT05187260研究中心2022-01 启动
  2. Pediatric Spinal Muscular Atrophy (SMA) China Registry进行中,不再招募NCT05042921研究中心2021-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

杜氏肌营养不良

Duchenne muscular dystrophy

2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

福州有 3 家医院列在杜氏肌营养不良下全国有 116 家医院列在杜氏肌营养不良下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

福州有 4 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Atrasentan in Patients With IgA Nephropathy进行中,不再招募NCT04573478研究中心III期2020-12 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年中国大陆作者发表的 161 篇先天性巨结肠 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

福州有 5 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

福建医科大学附属协和医院

Fujian Medical University Union Hospital

福州

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
FUjian Medical University Union Hospital; Union Hospital

提出更正下载数据